Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDXTAE)

Drug Name
ALXN1910 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMDXTAE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Alkaline phosphatase tissue-nonspecific (ALPL) TTMR5UV PPBT_HUMAN Replacement [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Alkaline phosphatase tissue-nonspecific (ALPL) DTT ALPL 6.35 4.07 5.7 3.609
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Alkaline phosphatase tissue-nonspecific (ALPL) DTT ALPL 4.67E-13 -0.15 -0.79
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05307978) A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1910 in Healthy Adult Participants. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Alexion